Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens
|
|
- Hollie Merilyn Curtis
- 5 years ago
- Views:
Transcription
1 O_05 Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens Linda Aurpibul MD. 1, Thition Narkbunnam MD. 2, Virat Sirisanthana MD. 1, Orasri Wittawatmongkol MD. 2, Wanatpreeya Phongsamart MD. 2, Tavitiya Sudjaritruk MD. 3, Tim R Cressey PhD. 4,5,6, Kulkanya Chokephaibulkit MD. 2 1 Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, 2 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 3 Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 4 Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand, 5 Harvard School of Public Health, Boston, MA, 6 Institut de Recherche pour le Développement (IRD), Marseille, France The study was supported by Government Pharmaceutical Organization, Thailand
2 Background Simplifying ART regimen is desirable in HIV-infected children and adolescents. In resource-limited setting, the combination of tenofovir, lamivudine plus efavirenz is the most affordable first line once-daily regimen. The study objectives were to determine the efficacy, safety, and adherence of this regimen in children.
3 A 48-week prospective, single arm, open label, multi-center study Study participants : 1.HIV-infected children 2.Aged between 3-18 years 3.Receiving a NNRTI-based regimen without TDF 4. HIV RNA level < 400 copies/ml 5. Weighing 15 kg Control group: Age, sex, and CD4 matched HIVinfected children on ART without TDF Switched to TDF/3TC/EFV once daily regimen Continued unchanged ARV treatment Assessments at 24-week interval CD4 Renal function (egfr, FECa, FEP) HIV RNA level Bone mineral density (DXA) Adherence & QOL assessment Clinical events
4 Materials and Methods At entry, the ART regimen was changed to a once daily TDF/3TC/EFV. Weight band(kg) Total daily dose (mg) Tenofovir (Oval-shaped scored tablet 300 mg) 15-< /2 22-< /4 > PENTA2009; recommended dose 8 mg/kg (for age < 8years) or 210mg/m 2 (for age >8years), acceptable range % is within 7-10 mg/kg or mg/m 2
5 Results Characteristics of study participants (n=80) Total Study Control p-value Characteristics group group (n=80) (n=40) (n= 40) Age, years (SD) 11.5(3.5) 11.7(3.5) 11.4(3.5) Male gender (%) 35(44) 18(45) 17(43) Body surface area, m 2 (SD) 1.13(0.26) 1.13(0.26) 1.13(0.26) CD4 lymphocyte count prior to ART initiation, cells/mm3 (SD) 617(798) 453(493) 785(1000) HAART regimen prior to study enrollment nevirapine-based 44(55) 23(58) 21(52) efavirenz-based 25(31) 17(42) 8(20) PI-based a 11(14) 0(0) 11(28) Mean duration on HAART prior to study enrollment, years (SD) 7.0(3.0) 6.7(2.6) 7.4(3.3) CD4 lymphocyte count at the time of study entry, cells/mm 3 (SD) 911(462) 857(425) 947(516) Number with HIV RNA level <400 copies/ml at study entry b 78(98) 40(100) 38(95) a Ten received lopinavir/ritonavir, one received darunvir/ritonavir B There were 2 participants in control group with HIV RNA level 403 and 635 copies/ml at entry
6 Results -Efficacy The mean TDF dose prescribed was 8.1 mg/kg (SD 1.0) or 210 mg/m 2 (SD 30) At week 48, thirty-nine of 40 children receiving TDF (97.5%) remained virologicsuppressed (HIV RNA level < 50 copies/ml). During the 48-week follow-up, 34 clinical events occurred in 23 children. None were classified as a serious adverse event or related to the study drugs.
7 Results-Renal safety There was a downward trend of egfr for study participants in both groups. No significant difference in change of egfr from baseline when compared between the study and control groups ( vs , p=0.82). None developed significant impaired glomerular function The fractional excretion of calcium and phosphate were slightly increased with time, but not clinically or statistically significant. No case with proteinuria, glucosuria. acidosis, hypokalemia or hyperuricemia.
8 Results-Bone safety There was a significant decrease in mean (SD) BMDZ among the group of children receiving TDF from 0.01(1.31) at baseline to -0.68(2.07) at week 24, and remained stable thereafter. Study group (children on TDF) At entry 1 children had BMDZ < -2.0 Three experienced low BMDZ at wk 24, two of 3 persisted to wk 48. One developed low BMDZ at wk 48. All except 1 of 5 had normal vitamin D level. Control group (children on other ART regimens) At entry 1 children had BMDZ < and persisted up to wk 48 At wk 24, two experienced low BMDZ, one persisted to wk 48 and another drop out after switching to second-line TDF-including regimen due to virologic failure. One developed low BMDZ at wk 48.
9 Results-Adherence and QOL All had > 95% treatment adherence.
10 Discussion (1) Low BMD has been reported in 24-32% of HIVinfected children on ART. 1,2 Similar to our finding, a decrease BMD in the first weeks on TDF was previously reported. 3,4 A 60-month follow-up study from the US reported no significant decrease in BMD among perinatally HIV-infected children and adolescents receiving TDF. 5 1 Puthanakit et al. JAIDS 2012;61: Schtscherbyna et al. Int J Infect Dis. 2012;16:e872-e Gafni et al. Pediatrics. 2006;118:e711-e Hazra et al. Pediatrics. 2005;116:e846-e Viganò et al. Clin Drug Investig. 2011;31:
11 Discussion (2) Previous observational cohort studies demonstrated the effect of TDF on renal function (either tubular or glomerular, or both) in pediatric populations. 1-5 Our prospective with control group study reported no change in glomerular function and no definite change in tubular function. BUT, there is a trend in decreasing tubular resorption of calcium and phosphorus. 1 Pontrelli et al. BMC Infect Dis 2012;12:18. 2 Soler-Palacín et al. AIDS 2011;25: Viganò et al. Clin Drug Investig 2011;31: Della Negra et al. Pediatr Infect Dis J 2012 ;31: Purswani et al. Pediatr Infect Dis J 2012 Dec 17. [Epub ahead of print]
12 Conclusions Switching to TDF/3TC/EFV in HIV-infected children was safe, effective, and favorable. This simplified regimen may improve adherence as well as quality of life. However, monitoring of BMD and renal function is important. Further study in larger sample size with extended follow-up period is required to determine long term adverse events associated with TDF use, as well as to identify markers for early detection of renal impairment.
18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa
A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationAttrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program
Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program Sirinya Teeraananchai 1,2, Thanyawee Puthanakit 1,3,4, Suchada Chaivooth
More informationLopinavir Hair Concentrations Predict Virological Failure Among Asian Children
Lopinavir Hair Concentrations Predict Virological Failure Among Asian Children Wasana Prasitsuebsai, Stephen J. Kerr, Truong Huu Khanh, Jintanat Ananworanich, Do Chau Viet, Nguyen Van Lam, Nia Kurniati,
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationIMPROVEMENT in LIPOATROPHY ASSOCIATED with HIGHLY ACTIVE ANTIRETROVIRAL THERAPY in HIV-INFECTED CHILDREN SWITCHED from STAVUDINE to TENOFOVIR
Poster R-105 IMPROVEMENT in LIPOATROPHY ASSOCIATED with HIGHLY ACTIVE ANTIRETROVIRAL THERAPY in HIV-INFECTED CHILDREN SWITCHED from STAVUDINE to TENOFOVIR ALESSANDRA VIGANO 1, PAOLO BRAMBILLA 1, LAURA
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationhiv/aids Programme Technical update on treatment optimization Use of tenofovir in HIV-infected children and adolescents: a public health perspective
hiv/aids Programme Technical update on treatment optimization Use of tenofovir in HIV-infected children and adolescents: a public health perspective June 2012 WHO Library Cataloguing-in-Publication Data
More informationHIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY Somnuek Sungkanuparph 1, Nopporn
More informationShort communication Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of
Antiviral Therapy 2010 15:1053 1058 (doi: 10.3851/IMP1650) Short communication Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths Alessandra
More informationResearch Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Hindawi BioMed Research International Volume 2017, Article ID 7481597, 14 pages https://doi.org/10.1155/2017/7481597 Research Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease
More informationHighly active antiretroviral therapy (HAART) has dramatically
HIV Re p o r t s Recovery From Lipodystrophy in HIV infected Children After Substitution of Stavudine With Zidovudine in a n-nucleoside Reverse Transcriptase Inhibitor based Antiretroviral Therapy Linda
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationActive TB in HIV-infected children in Thailand: Prevalence, incidence and mortality
O_17 Active TB in HIV-infected children in Thailand: Prevalence, incidence and mortality N. Salvadori 1, P. Riyaten 1, S. Thongsak 1, S. Chalermpantmetagul 1, P. Traisathit 1,2, C. Ngampiyaskul 3, S. Hanpinitsak
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationRenal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
Original Article Vol. 29 No. 3 Renal safety of tenofovir:- Wiwattanathum P & Sungkanuparph S. 113 Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
More informationTitle: What ARV regimen to start in children 3 years old? (TDF)
Title: What ARV regimen to start in children 3 years old? (TDF) Contents 1. PICO question... 1 2. Search strategy... 1 3. Flow diagram of screening process... 2 4. Evidence summaries... 2 5. Bibliography
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationAcquired HIV Drug Resistance in children in Asia
Acquired HIV Drug Resistance in children in Asia Jintanat Ananworanich, MD, PhD Pediatrician/Immunologist Deputy Director in Scientific Affairs, HIV-NAT Chief, SEARCH The Thai Red Cross AIDS Research Centre
More informationThe widespread use of antiretroviral therapy (ART) for the
ORIGINAL STUDIES Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor Based Antiretroviral Therapy Podjanee
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationAll HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!!
All HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!! Lynne Mofenson MD Elizabeth Glaser Pediatric AIDS Foundation My Esteemed Opponent Will Likely
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 30 Dec 2018 00:34:16 GMT) CTRI Number CTRI/2009/091/000652 [Registered on: 27/10/2009] - Last Modified On 11/03/2014 Post Graduate Thesis Type of Trial
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationINTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
More informationPediatric Antiretroviral Therapy
Update on Pediatric Antiretroviral Therapy Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:
More informationRenal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
RESEARCH ARTICLE Open Access Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors Giuseppe Pontrelli *, Nicola Cotugno *, Donato Amodio,
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationOdefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological
More informationFIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationInfertility Treatment and HIV
Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationEfficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children
International Journal of Infectious Diseases (2008) 12, e33 e38 http://intl.elsevierhealth.com/journals/ijid Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected
More information1 Introduction. Vania Giacomet 1 Pilar Nannini. Annarita Benincaso 1 Giorgio Bedogni. Gian Vincenzo Zuccotti 4
Clin Drug Investig DOI 10.1007/s40261-015-0293-7 ORIGINAL RESEARCH ARTICLE Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationApatcha Pungjitprapai, M.D., Mattana Hanvanich, M.D. Abstract of Infectious Diseases Fellows
of Infectious Diseases Fellows A Study of Plasma HIV RNA Viral Load Response to the Treatment with Low Dose Stavudine (D4T) in Lamivudine (3TC) and Efavirenz Containing Highly Active Antiretroviral Regimen
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationMultisystem Impairment in Perinatally HIV-infected (PHIV) South African Adolescents
Multisystem Impairment in Perinatally HIV-infected (PHIV) South African Adolescents Lisa Frigati, Karryn Brown, Sana Mahtab, Leah Githinji, Diane Gray, Liesel Zuhlke, ሷ Jaqueline Hoare, Mark Cotton, Landon
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationCreating a broader-based response to treatment failure and HIV drug resistance
Creating a broader-based response to treatment failure and HIV drug resistance Addy Chen Coordinator, MSM+ Working Group Asia Pacific Network of People Living with HIV/AIDS (APN+) Treatment Failure in
More informationOriginal article Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai children
Antiviral Therapy 14:315 320 Original article Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai children Thanyawee Puthanakit 1, Pranoot Tanpaiboon
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationSafety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008
Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile
More informationMeasles, Mumps and Rubella Seropositivity in Children with Perinatal HIV Infection
Measles, Mumps and Rubella Seropositivity in Children with Perinatal HIV Infection George Siberry, Li Liu, William Bellini (CDC), Sandy Burchett, Murli Purswani, William Meyer, Kunjal Patel, Russ Van Dyke
More informationEmtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationBinge drinking decreases weekend adherence in a RCT from low and middle income countries
Binge drinking decreases weekend adherence in a RCT from low and middle income countries Raquel B. De Boniᵃ Lu Zhengᵇ, Susan Rosenkranzᵇ, Xin Sunᵇ, Sandra Wagnerᵃ, Beatriz Grinsztejnᵃ, Alberto La Rosaᶜ,
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationTDF Renal Dysfunction
TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationDownloaded from:
Dakshina, S; Olaru, I; Khan, P; Raman, L; McHugh, G; Bwakura, M; Nathoo, K; Munyati, S; Mujuru, H; Ferrand, Rashida (2019) Evaluation of weight-based prescription of antiretroviral therapy in children.
More informationPaediatric European Network for Treatment of AIDS
Paediatric European Network for Treatment of AIDS KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets
More informationEU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3
VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationHealth-related quality of life of perinatally HIV-infected adolescents.
Curr Pediatr Res 2016; 20 (1&2): 231-237 ISSN 0971-9032 www.currentpediatrics.com Health-related quality of life of perinatally HIV-infected adolescents. Linda Aurpibul 1, Peninnah Oberdorfer 2, Worawut
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationRenal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More information